Abstract 1247P
Background
Volatile organic compounds (VOCs) are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. In this study, we aimed to investigate the potential of VOCs analysis as a non-invasive method for early detection of EGFR mutation.
Methods
We collected breath samples from 114 EGFR wild-type lung adenocarcinoma patients and 132 EGFR mutant lung adenocarcinoma patients and analyzed them using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry (HPPl-TOFMS) to detect VOCs. A detection model for EGFR mutation based on VOC analysis was established using the eXtreme Gradient Boosting (XGB) algorithm. For building the EGFR mutation detection model, all the samples were randomly split into a training set, validation set, and test set with a ratio of 5:2:3.
Results
The top ten VOC ions which were significantly different between the EGFR mutant lung adenocarcinoma patients and patients without EGFR mutation were displayed in the table (P < 0.05). The discrimination power of each VOC was relatively limited. Among them, 2-Ethyl-4,5-dimethylthiazole had the highest accuracy with an area under the receiver operating characteristic curve (AUC) of 0.829 (95%CI: 0.744-0.974). With the combination of these 10 VOC ions, the model performs well. The AUC for the combination model was 0.895 (95% CI: 0.810-0.980) in the validation cohort, while the AUC in the test set was 0.849 (95% CI: 0.769-0.930), indicating good diagnostic accuracy, with sensitivity and specificity of 70.7% (95% CI: 56.6%, 84.4%) and 71.4% (95% CI: 56.2%, 86.6%). Table: 1247P
The top 10 VOC ions related to EGFR mutation in lung adenocarcinoma
Chemicals | Peak area | P-value | |
EGFR mut | RGFR wild | ||
Cyclohexanone oxime | 242.6±103.4 | 139.1±234.1 | <0.001 |
Dimethoxybenzene | 522.7±1730.2 | 200.0±256.6 | 0.017 |
Tert-Butyl methyl ether | 667.5±1655.3 | 278.4±302.0 | 0.006 |
2-Ethyl-4,5-dimethylthiazole | 659.0±1762.2 | 329.7±730.8 | 0.039 |
Trimethylbenzene | 375.1±617.7 | 202.9±185.6 | <0.001 |
Salicylamide | 310.6±332.9 | 203.0±187.3 | <0.001 |
p-cymene/Cinnamyl alcohol | 300.5±1002.5 | 123.5±130.7 | 0.038 |
L-serine/D-serine | 706.2±515.0 | 359.9±318.0 | <0.001 |
1-Propanethiol | 2005.3±1609.7 | 1419.7±1673.0 | 0.002 |
4-Methylanisole/2-Methylanisole | 402.1±314.4 | 180.1±220.1 | <0.001 |
Conclusions
Our study suggested that VOCs analysis might be useful as non-invasive methods for early detection of EGFR mutations in lung adenocarcinoma. Further studies are needed to validate the accuracy of our model.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Chinese National Natural Science Foundation Project; China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14